[癌性心脏病的治疗选择]
Rickard Lindblom1, Staffan Welin2, Johan Forsblad3
1docent, överläkare, toraxkirurgi, Akademiska sjuk-huset, Uppsala.
概括
神经内分泌瘤 (NETs) 可能导致癌性心脏病,导致右侧心力衰竭. 门置换可以有所帮助,但正在出现新的跨导管选择来治疗这些心脏病.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 神经内分泌瘤 (NETs) 是一组多样化的癌症,通常起源于胃肠道.
- NETs可以通过局部生长和激素产生引起重大疾病,影响系统生理学.
- 癌症性综合征,与转移性NET相关,影响大约20%的患者,导致癌症性心脏病.
研究的目的:
- 讨论癌症性心脏病对神经内分泌瘤患者的影响.
- 审查当前的治疗策略,包括用于癌性心脏病的门置换.
- 探索对影响三管和肺门的癌性心脏病的新兴透导管治疗选择.
主要方法:
- 关于神经内分泌瘤,癌症综合征和癌症性心脏病的文献综述.
- 对癌性心脏病中门置换治疗结果的分析.
- 对NET患者的膜心脏病的当前和新型跨导管干预措施的概述.
主要成果:
- 癌性心脏病通常表现为右侧心力衰竭,由于三管和肺的恶化.
- 手术门置换可以缓解心力衰竭症状,并改善受影响患者的存活率.
- 由于NETs的慢性荷尔蒙活性,生物假体门可能过早退化.
结论:
- 癌症性心脏病是转移性NET和癌症性综合征的重要并发症.
- 门更换是一个关键的干预措施,尽管生物假体门的耐用性可能令人担忧.
- 过导管治疗是治疗癌性心脏病的有希望的进步,为内和初级干预提供了潜力.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
Heart Failure Drugs: Inotropic Agents
401
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
401
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
89
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
89
Barrett Esophagus-II: Clinical Manifestations and Management
73
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
73
Heart Failure Drugs: β-Blockers
259
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K


